Zhejiang Shengda Bio-Pharm Co., Ltd. (603079) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zhejiang Shengda Bio-Pharm Co., Ltd.

Why is Zhejiang Shengda Bio-Pharm Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 2,670.04%

The company has been able to generate a Return on Capital Employed (avg) of 2,670.04% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of 0.67% and Operating profit at -21.60% over the last 5 years

The company has declared Positive results for the last 3 consecutive quarters

OPERATING CASH FLOW(Y) Highest at CNY 133.3 MM
NET PROFIT(HY) At CNY 31.63 MM has Grown at 77.05%
ROCE(HY) Highest at 4.32%

With ROE of 3.74%, it has a attractive valuation with a 2.09 Price to Book Value

Over the past year, while the stock has generated a return of 27.47%, its profits have risen by 303.4% ; the PEG ratio of the company is 0.2

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Zhejiang Shengda Bio-Pharm Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Zhejiang Shengda Bio-Pharm Co., Ltd.

-31.26%

1.78

38.87%

China Shanghai Composite

20.18%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-0.68%

EBIT Growth (5y)

-22.52%

EBIT to Interest (avg)

-2.52

Debt to EBITDA (avg)

0.27

Net Debt to Equity (avg)

0.07

Sales to Capital Employed (avg)

0.46

Tax Ratio

21.72%

Dividend Payout Ratio

30.16%

Pledged Shares

Institutional Holding

ROCE (avg)

2,670.04%

ROE (avg)

1,212.89%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.53

EV to EBIT

11.21

EV to EBITDA

5.42

EV to Capital Employed

0.47

EV to Sales

0.79

PEG Ratio

1.33

Dividend Yield

ROCE (Latest)

4.16%

ROE (Latest)

3.82%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 159.34 MM

RAW MATERIAL COST(Y)

Fallen by -1.88% (YoY

CASH AND EQV(HY)

Highest at CNY 1,253.45 MM

DEBT-EQUITY RATIO (HY)

Lowest at -11.49 %

-8What is not working for the Company

NET PROFIT(HY)

At CNY 21.94 MM has Grown at -25.5%

OPERATING PROFIT(Q)

Lowest at CNY 18.65 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 9.86 %

NET SALES(Q)

Lowest at CNY 189.22 MM

Here's what is working for Zhejiang Shengda Bio-Pharm Co., Ltd.

Operating Cash Flow

Highest at CNY 159.34 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Cash and Eqv

Highest at CNY 1,253.45 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -11.49 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -1.88% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Zhejiang Shengda Bio-Pharm Co., Ltd.

Operating Profit

Lowest at CNY 18.65 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 9.86 % and Fallen

In each period in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Net Profit

At CNY 21.94 MM has Grown at -25.5%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

Net Sales

Lowest at CNY 189.22 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Net Sales

At CNY 189.22 MM has Fallen at -10.38%

over average net sales of the previous four periods of CNY 211.13 MM

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)